Empower Clinics Inc.
4.8.2021 12:41:43 CEST | ACCESS Newswire | Press release
The newly expanded facility substantially enhances KAI LAB's research and service testing capabilities
VANCOUVER, BC / ACCESSWIRE / August 4, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens is delighted to announce the completion of its Kai Medical Laboratory ("Kai Lab") expansion.
Acquired by Empower Clinics on October 6, 2020, Kai Lab's Texas facility represents best-in-class testing capabilities. Since Q4 2020, Kai Labs has been a consistent revenue driver for the Company by meeting the needs of enterprise clients focused on cultivating a safer work environment. Thus far in 2021, Kai labs has yielded consistent and promising growth for Empower Clinics.
"I'm immensely proud the Kai Lab team for completing this monumental expansion," said Steven McAuley, Chairman and CEO of Empower. "This endeavor has unleashed Kai Lab's full potential to become a leader in both enterprise and direct to consumer testing, a matter of utmost important as individuals and businesses prepare for another flu season."
"After months of hard work, I'm thrilled to see the successful completion of Kai Lab's crucial expansion," said Yoshi Tyler, President of Kai Labs. "Through the leadership and expertise of the Empower Team we continue to make strides in meeting the demands of North America's healthcare space."
In addition to expanding the volume of current testing services, this milestone brings new product and service offerings to Kai Labs, such as dried blood spot card-based testing, vitamine, and hormone testing. Kai Labs also invested in its future beyond the COVID-19 pandemic by augmenting its research and development endeavors and its ability to collect a variety of specimen samples for testing. New testing offerings will include saliva and swab-based testing, respiratory pathogen panel, urinary tract and sexually transmitted infections testing. A ceremony to launch the expanded Kai Labs is slated for Fall 2021.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
CONTACTS:
Investors:
Steven McAuley CEO
s.mcauley@empowerclinics.com
604-789-2146
Investors:
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
View source version on accesswire.com:
https://www.accesswire.com/658328/Empower-Clinics-Completes-Landmark-Kai-Laboratory-Expansion
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Maxon Announces Free Tools and Mobile Expansion of ZBrush and Cinema 4D16.4.2026 16:55:00 CEST | Press release
Cinema 4D brings professional 3D workflows to iPad. The return of Autograph - now free for individual users. ZBrush expands to Windows on Arm. See it all at NAB 2026. BAD HOMBURG, GERMANY / ACCESS Newswire / April 16, 2026 / Maxon, a leading developer of powerful and intuitive 2D and 3D software and complete graphic design workflows, today announced a major step forward in its mission to make professional creative tools more accessible to artists everywhere. With the debut of Cinema 4D on iPad, the return of the Autograph motion graphics application, and the expansion of Maxon tools to Windows on Arm (WoA) tablet devices, Maxon is lowering the barrier to entry while empowering artists to work where they want, how they want. Visitors to NAB 2026 can see it all at the Maxon booth (N2741). Professional Tools, Broader Access As demand for 3D and motion content accelerates across social media, streaming, gaming, and immersive media, creators are seeking flexible and affordable entry points
Maxon Announces Free Tools and Mobile Expansion of ZBrush and Cinema 4D16.4.2026 16:55:00 CEST | Press release
Cinema 4D brings professional 3D workflows to iPad. The return of Autograph - now free for individual users. ZBrush expands to Windows on Arm. See it all at NAB 2026. BAD HOMBURG, GERMANY / ACCESS Newswire / April 16, 2026 / Maxon, a leading developer of powerful and intuitive 2D and 3D software and complete graphic design workflows, today announced a major step forward in its mission to make professional creative tools more accessible to artists everywhere. With the debut of Cinema 4D on iPad, the return of the Autograph motion graphics application, and the expansion of Maxon tools to Windows on Arm (WoA) tablet devices, Maxon is lowering the barrier to entry while empowering artists to work where they want, how they want. Visitors to NAB 2026 can see it all at the Maxon booth (N2741). Professional Tools, Broader Access As demand for 3D and motion content accelerates across social media, streaming, gaming, and immersive media, creators are seeking flexible and affordable entry points
Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 202616.4.2026 15:20:00 CEST | Press release
Built on Available Infrastructure's SanQtum AI quantum-resistant edge platform, the 48,000-GPU fleet targets enterprises facing extended GPU lead times - with DataValue®, DataScore®, and Information Data Exchange® (IDE®) tokenization built in PHILADELPHIA, PA / ACCESS Newswire / April 16, 2026 / The global AI compute shortage has forced enterprises outside the hyperscaler customer set to wait extended periods for high-performance GPU capacity. Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the first sites of its new quantum-ready high-performance computing ("HPC") GPU network are now live in New York and Philadelphia, with commercial availability of the full 48,000-GPU fleet beginning in Q3 2026. The fleet will be distributed across 1,000 urban micro-edge neocloud sites in more than 100 U.S. cities by the end of 2026. Each
Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 202616.4.2026 15:20:00 CEST | Press release
Built on Available Infrastructure's SanQtum AI quantum-resistant edge platform, the 48,000-GPU fleet targets enterprises facing extended GPU lead times - with DataValue®, DataScore®, and Information Data Exchange® (IDE®) tokenization built in PHILADELPHIA, PA / ACCESS Newswire / April 16, 2026 / The global AI compute shortage has forced enterprises outside the hyperscaler customer set to wait extended periods for high-performance GPU capacity. Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the first sites of its new quantum-ready high-performance computing ("HPC") GPU network are now live in New York and Philadelphia, with commercial availability of the full 48,000-GPU fleet beginning in Q3 2026. The fleet will be distributed across 1,000 urban micro-edge neocloud sites in more than 100 U.S. cities by the end of 2026. Each
Camino Corporation Commences Drilling at Costa de Cobre District-Scale IOCG Copper Discovery in Peru16.4.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 16, 2026 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce the commencement of a drilling campaign at its Costa de Cobre district-scale IOCG copper discovery in Peru ("Costa de Cobre" or "Copper Coast"), previously referred to as the Los Chapitos copper project(1). Camino has rebranded the Los Chapitos project as the Costa de Cobre, the Copper Coast, to better reflect its low-elevation coastal setting and strategic proximity to key infrastructure, including the proposed San Juan de Marcona Port Terminal, a major new port facility planned approximately 125 km to the north at Marcona. The Costa de Cobre project is advancing to the next stage of exploration and development as the Company enters into a joint venture with Nittetsu Mining Co., Ltd.("Nittetsu"), under which Camino will serve as operator and hold a 65% interest, while Nittetsu will hold the remaining 35% interest. Camino is also d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
